Impact of concomitant use of opicapone during levodopa–carbidopa intestinal gel treatment

•The impact of opicapone plus LCIG in patients with Parkinson's disease is unclear.•Pharmacokinetic evaluation of LCIG and opicapone was performed in a patient.•Concomitant use of opicapone with LCIG increased AUC0–8 of levodopa by 60%.•Concomitant use of opicapone with LCIG reduced AUC0–8 of 3...

Full description

Saved in:
Bibliographic Details
Published inJournal of the neurological sciences Vol. 445; p. 120549
Main Authors Miyaue, Noriyuki, Ito, Yuko H., Ochi, Chikako, Yamanishi, Yuki, Tada, Satoshi, Ando, Rina, Nagai, Masahiro
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.02.2023
Subjects
3–O–methyldopa
Antiparkinson Agents - adverse effects
Carbidopa - adverse effects
Drug Combinations
Humans
Levodopa - adverse effects
Levodopa pharmacokinetics
Levodopa–carbidopa intestinal gel
Opicapone
Oxadiazoles
Parkinson's disease
3–O–methyldopa
3–OMD
Parkinson's disease
Levodopa pharmacokinetics
PD
LCIG
Opicapone
Levodopa–carbidopa intestinal gel
COMT
AUC
Online AccessGet full text

Cover

More Information
Summary:•The impact of opicapone plus LCIG in patients with Parkinson's disease is unclear.•Pharmacokinetic evaluation of LCIG and opicapone was performed in a patient.•Concomitant use of opicapone with LCIG increased AUC0–8 of levodopa by 60%.•Concomitant use of opicapone with LCIG reduced AUC0–8 of 3–OMD by 78%.•Addition of opicapone may have effects beyond changes in levodopa pharmacokinetics.
ISSN:0022-510X
1878-5883
DOI:10.1016/j.jns.2023.120549